Antibody-drug conjugates (ADCs) are expanding precision oncology, with promising biomarkers like Trop-2, Nectin-4, and folate receptor alpha (FRα) showing potential across multiple tumor entities.<h4>Methods</h4>Tumors were analyzed using the TSO500® panel, enabling tumor mutational burden (TMB) readout. Here, TACSTD2 is linked to neoplasm.